GenMont Biotech Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, sales was TWD 167.55 million compared to TWD 186.45 million a year ago. Net income was TWD 11.13 million compared to TWD 35.02 million a year ago. Basic earnings per share from continuing operations was TWD 0.13 compared to TWD 0.41 a year ago. Diluted earnings per share from continuing operations was TWD 0.13 compared to TWD 0.4 a year ago.